Live
FierceBiotechLilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trialEndpoints NewsCongruence starts human trials for first drug, raises $40MEndpoints NewsLantern raises $30M from Morgan Health, Echo Health VenturesThermo FisherMirova Trims Position in Thermo Fisher Scientific Inc. $TMO - MarketBeatEndpoints NewsUpdated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggestThermo FisherGroupama Asset Management Boosts Thermo Fisher Scientific Holdings - National TodayIlluminaJPMorgan Chase Boosts Illumina Stake by 17.5% - National TodayIlluminaJPMorgan Chase & Co. Acquires 124,246 Shares of Illumina, Inc. $ILMN - MarketBeat10x Genomics Blog10x Genomics CRISPR Brain Atlas Collaboration And What It Means For Investors - Yahoo Finance SingaporeWatersIs Waters Corporation Stock Underperforming the Dow? - BarchartWatersIs Waters Corporation Stock Underperforming the Dow? - FinancialContentWatersIs Waters Corporation Stock Underperforming the Dow? - Yahoo Finance
FierceBiotech Jan 27, 2026

Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets

Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets

Original
Body unavailable. Use the original source.

Directory

59 All